GFR-话题@MedSci

#GFR#

483篇内容 | 2528人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534261, encodeId=4336153426188, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CSCO 2014：亚洲EGFR突变NSCLC患者的治疗新机会, objectType=article, longId=40490, objectId=4b40404902e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b40404902e, replyNumber=0, likeNumber=0, createdTime=2014-09-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b40404902e, moduleTitle=CSCO 2014：亚洲EGFR突变NSCLC患者的治疗新机会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b40404902e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534259, encodeId=fff21534259c9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=中国 EGFR 基因敏感突变和 ALK 融合基因阳性 NSCLC 诊疗指南, objectType=article, longId=40251, objectId=4e434025139, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e434025139, replyNumber=0, likeNumber=64, createdTime=2014-09-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e434025139, moduleTitle=中国 EGFR 基因敏感突变和 ALK 融合基因阳性 NSCLC 诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e434025139)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534258, encodeId=0d91153425890, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nat Cell Biol：奥地利研究发现EGFR致癌新机制, objectType=article, longId=40171, objectId=506b401e129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=506b401e129, replyNumber=0, likeNumber=69, createdTime=2014-09-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=506b401e129, moduleTitle=Nat Cell Biol：奥地利研究发现EGFR致癌新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=506b401e129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534257, encodeId=cdb0153425e26, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JTO：EGFR突变和肿瘤组织DNA突变直接相关, objectType=article, longId=40086, objectId=7d2b400866f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d2b400866f, replyNumber=0, likeNumber=77, createdTime=2014-09-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d2b400866f, moduleTitle=JTO：EGFR突变和肿瘤组织DNA突变直接相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d2b400866f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534256, encodeId=2ec515342560d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Stroke：低eGFR可预测急性卒中糖尿病者转归, objectType=article, longId=39227, objectId=6ca13922e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ca13922e0e, replyNumber=0, likeNumber=73, createdTime=2014-08-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ca13922e0e, moduleTitle=Stroke：低eGFR可预测急性卒中糖尿病者转归, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ca13922e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534255, encodeId=54f0153425594, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JTO：EGFR 基因突变型 NSCLC 体积倍增时间长, objectType=article, longId=38945, objectId=f7ce38945ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7ce38945ac, replyNumber=0, likeNumber=71, createdTime=2014-08-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7ce38945ac, moduleTitle=JTO：EGFR 基因突变型 NSCLC 体积倍增时间长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7ce38945ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534254, encodeId=50141534254a2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CSMO 2014：EGFR抑制剂的新进展与新思路, objectType=article, longId=38107, objectId=26de3810e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26de3810e26, replyNumber=0, likeNumber=99, createdTime=2014-07-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26de3810e26, moduleTitle=CSMO 2014：EGFR抑制剂的新进展与新思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26de3810e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534253, encodeId=bed3153425338, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, objectType=article, longId=37824, objectId=30183e824a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30183e824a7, replyNumber=0, likeNumber=73, createdTime=2014-07-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30183e824a7, moduleTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30183e824a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534252, encodeId=8a4e15342524b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CSMO 2014：晚期非小细胞EGFR抑制剂的新进展与新思路, objectType=article, longId=37551, objectId=fad13e55151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fad13e55151, replyNumber=0, likeNumber=115, createdTime=2014-07-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fad13e55151, moduleTitle=CSMO 2014：晚期非小细胞EGFR抑制剂的新进展与新思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fad13e55151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534251, encodeId=6f831534251c6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）, objectType=article, longId=36430, objectId=2a7d3643000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7d3643000, replyNumber=0, likeNumber=59, createdTime=2014-06-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7d3643000, moduleTitle=厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7d3643000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534250, encodeId=cf34153425004, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）, objectType=article, longId=36429, objectId=9c3c36429bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3c36429bc, replyNumber=0, likeNumber=110, createdTime=2014-06-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3c36429bc, moduleTitle=厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3c36429bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534249, encodeId=9fe2153424918, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, objectType=article, longId=36428, objectId=00fd3642874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00fd3642874, replyNumber=0, likeNumber=59, createdTime=2014-06-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00fd3642874, moduleTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00fd3642874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534248, encodeId=733f15342488c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014肺癌专场：中国3项EGFR靶向辅助治疗试验, objectType=article, longId=35935, objectId=687b35935f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=687b35935f4, replyNumber=0, likeNumber=60, createdTime=2014-06-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=687b35935f4, moduleTitle=ASCO 2014肺癌专场：中国3项EGFR靶向辅助治疗试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=687b35935f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534247, encodeId=2794153424e98, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, objectType=article, longId=35735, objectId=b22c35e35e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22c35e35e3, replyNumber=0, likeNumber=57, createdTime=2014-06-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22c35e35e3, moduleTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b22c35e35e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534239, encodeId=f631153423963, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验, objectType=article, longId=35667, objectId=f1cf3566e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf3566e12, replyNumber=0, likeNumber=62, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf3566e12, moduleTitle=ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1cf3566e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534240, encodeId=e34e153424088, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验, objectType=article, longId=35668, objectId=21d935668a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21d935668a7, replyNumber=0, likeNumber=74, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21d935668a7, moduleTitle=ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21d935668a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534241, encodeId=2ed415342415d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性, objectType=article, longId=35671, objectId=7538356e136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7538356e136, replyNumber=0, likeNumber=61, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7538356e136, moduleTitle=ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7538356e136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534242, encodeId=a3541534242f9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：NSCLC患者血清循环DNA的EGFR突变检测, objectType=article, longId=35689, objectId=d395356899c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d395356899c, replyNumber=0, likeNumber=80, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d395356899c, moduleTitle=ASCO 2014：NSCLC患者血清循环DNA的EGFR突变检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d395356899c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534243, encodeId=21cb15342433d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, objectType=article, longId=35691, objectId=a7ba35691f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ba35691f6, replyNumber=0, likeNumber=92, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ba35691f6, moduleTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ba35691f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534244, encodeId=8d3815342449b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析, objectType=article, longId=35696, objectId=1f4c3569670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f4c3569670, replyNumber=0, likeNumber=68, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f4c3569670, moduleTitle=ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f4c3569670)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CSCO 2014：亚洲EGFR突变NSCLC患者的治疗新机会

2014-09-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

中国 EGFR 基因敏感突变和 ALK 融合基因阳性 NSCLC 诊疗指南

2014-09-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Nat Cell Biol：奥地利研究发现EGFR致癌新机制

2014-09-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JTO：EGFR突变和肿瘤组织DNA突变直接相关

2014-09-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Stroke：低eGFR可预测急性卒中糖尿病者转归

2014-08-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JTO：EGFR 基因突变型 NSCLC 体积倍增时间长

2014-08-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CSMO 2014：EGFR抑制剂的新进展与新思路

2014-07-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移

2014-07-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CSMO 2014：晚期非小细胞EGFR抑制剂的新进展与新思路

2014-07-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）

2014-06-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）

2014-06-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

三种第三代EGFR-TKI药物有望将来用于NSCLC

2014-06-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014肺癌专场：中国3项EGFR靶向辅助治疗试验

2014-06-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效

2014-06-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：埃克替尼+全脑放疗脑转移的EGFR突变NSCLC患者的I期试验

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：NSCLC患者血清循环DNA的EGFR突变检测

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析

2014-06-02

科室
- - 订阅+
  - 更多科室
工具
服务